Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera , atomoxetine hydrochloride capsules.
These generic atomoxetine hydrochloride capsules are equivalent to Eli Lilly?s Strattera capsules and include six strengths: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, and 100 mg.
Annual sale in US for these strengths of branded and generic atomoxetine hydrochloride capsules is estimated at over $ 530 million.
Atomoxetine Hydrochloride capsules are indicated for the management of attention deficit hyperactivity disorder in children aged 6 and older,teens and adults.
Stattera is a registered trademark of Eli Lilly and Co.